has function has role immunizes against disease immunizes recipient melanoma Homo sapiens melanoma vaccine therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role therapeutic cancer vaccine PD-L1/IDO peptide vaccine IO102-103 Gene name: IDO 3620 6337 NCT: https://clinicaltrials.gov/study/NCT03047928 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148154 cancer vaccine Gene name: PD-L1 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6337 Jie Zheng Hayleigh Kahn A cancer vaccine composed of IO103, a peptide derived from the tumor-associated antigen (TAA) programmed cell death-1 ligand 1 (PD-L1), IO102, the 21-mer peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), and the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Both IDO and PD-L1 reactive CD8 T cells are cytotoxic and can kill cancer cells and immune regulatory cells in vitro. Thus boosting specific T cells that recognize immune regulatory proteins such as IDO and PD-L1 may directly modulate immune regulation. The the programmed death 1 (PD-1) regulatory antibody Nivolumab may further help treat patients with metastatic melanoma. 29126